Prospective study of plasma enterolactone and prostate cancer risk (Sweden)

Cancer Causes and Control

Volumn 15, Issue 10, 2004, Pages 1095-1102

  Stattin, Pär ^a   Bylund, Annika ^a   Biessy, Carine ^b   Kaaks, Rudolf ^b   Hallmans, Göran ^a   Adlercreutz, Herman ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Enterolactone; Nested case control study; Plasma; Prostate cancer risk

Indexed keywords

ENTEROLACTONE; 2,3 BIS(3' HYDROXYBENZYL)BUTYROLACTONE; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; DRUG DERIVATIVE; GAMMA BUTYROLACTONE; LIGNAN; PHYTOESTROGEN;

ADULT; AGE; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; FLUOROIMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SMOKING; SWEDEN; BLOOD; COHORT ANALYSIS; LIFESTYLE; MIDDLE AGED; OBESITY; PROSTATE TUMOR; RISK;

4-BUTYROLACTONE; COHORT STUDIES; HUMANS; LIFE STYLE; LIGNANS; MALE; MIDDLE AGED; OBESITY; PHYTOESTROGENS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; SMOKING; SWEDEN;

EID: 17844379993     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-004-1480-7     Document Type: Article

References (34)

1. Adlercreutz H, Mazur W (1997) Phyto-oestrogens and Western diseases. Ann Med 29: 95-120.
2. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A (1998) Phytoestrogens; where are we now? Br J Nutr 79: 393-406.
3. Saarinen NM, Warri A, Makela SI, et al. (2000) Dietary phytoestrogens and their role in hormonally dependent disease. Nutr Cancer 36: 207-216.
4. Adlercreutz A (1998) Human health and phytoestrogens. In: Korach KS ed. Reproductive and Developmental Toxicology. New York, pp. 299-371.
5. Landström M, Zhang JX, Hallmans G, et al. (1998) Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36: 151-161.
6. Bylund A, Zhang JX, Bergh A, et al. (2000) Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 42: 304-314.
7. Demark-Wahnefried W, Price DT, Polascik TJ, et al. (2001) Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 58: 47-52.
8. Owen RW, Mier W, Giacosa A, Hull WE, Spiegelhalder B, Bartsch H (2000) Identification of lignans as major components in the phenolic fraction of olive oil. Clin Chem 46: 976-988.
9. Heinonen S, Nurmi T, Liukkonen K, et al. (2001) In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 49: 3178-3186.
10. Bylund A, Lundin E, Zhang JX, et al. (2003) Randomised controlled short-term intervention pilot study on rye bran bread in prostate cancer. Eur J Cancer Prev 12: 407-415.
11. Stattin P, Adlercreutz H, Tenkanen L, et al. (2002) Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 99: 124-129.
12. Kilkkinen A, Virtamo J, Virtanen MJ, Adlercreutz H, Albanes D, Pietinen P (2003) Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study. Cancer Epidemiol Biomarkers Prev 12: 1209-1212.
13. Weinehall L (1997) Partnership for health on the role of primary health care in a community intervention programme. Umeå University Medical Dissertations ISSN 0346-6612-ISBN 91-7191-388-2. Umeå University, Umeå.
14. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S (1998) Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 16: 171-176.
15. Stattin P, Bylund A, Rinaldi S, et al. (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917.
16. Adlercreutz H, Wang GJ, Lapcik O, et al. (1998) Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 265: 208-215.
17. Stumpf K, Uehara M, Nurmi T, Adlercreutz H (2000) Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. Anal Biochem 284: 153-157.
18. Stattin P, Söderberg S, Hallmans G, et al. (2001) Leptin is associated with increased prostate cancer risk. A nested-case-referent study. J Clin Endocrinol Metab 86: 1341-1345.
19. Stattin P, Lumme S, Tenkanen L, et al. (2004) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108: 418-424.
20. Cary E (1989) SAS Institute Inc. SAS/STAT User's Guide Version 6.4.
21. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H (2001) Determinants of serum enterolactone concentration. Am J Clin Nutr 73: 1094-1100.
22. Hultén K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G (2002) An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 41: 168-176.
23. Stumpf K, Pietinen P, Puska P, Adlercreutz H (2000) Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland. Cancer Epidemiol Biomarkers Prev 9: 1369-1372.
24. Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H (2002) Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 155: 472-477.
25. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985-1992.
26. Zeleniuch-Jaccquotte A, Adlercreutz H, Ahmedkhanov A, Toniolo P (1998) Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 7: 885-889.
27. Kaaks R, Lukanova A, Sommersberg B (2000) Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 3: 157-172.
28. Saarinen NM, Huovinen R, Warri A, et al. (2002) Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther 1: 869-876.
29. Adlercreutz H, Mousavi Y, Clark J, et al. (1992) Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Molec Biol 41: 331-337.
30. Bianchini Saarinen NM, Warri A, et al. (2000) Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer 36: 207-216.
31. Kaaks R, Lukanova A, Sommersberg B (2000) Plasma androgens, IGF-I, body size and prostate cancer risk, Kaaks R, Vainio H (2002) Overweight, obesity, and cancer risk. Lancet Oncol 3: 565-574.
32. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638.
33. World Cancer Research Fund /ifcr (1997) Prostate. Food, Nutrition and the Prevention of Cancer: A Global Perspective. BANTA Book Group, Menasha, WI, USA, pp. 310-323
34. Key TJ, Allen N, Appleby P, et al. (2004) Fruits and vegetables and prostate cancer: No association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109: 119-124.